A Study to Investigate the Effect of Mirabegron (YM178) on Subjects With Mild or Moderate Hepatic Impairment Compared to Healthy Subjects

NCT01579461 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Pharmacokinetics
Healthy Subjects
Mild and Moderate Hepatic Impairment

Interventions

DRUG: mirabegron

Sponsor

Astellas Pharma Europe B.V.